Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma: A Single-Arm, Open-Label, Multicenter, Phase II Study

Authors not listed

Sun Yat-sen University · 2025

Abstract

This is a single- arm, open-label, multicenter, phase II study to evaluate Acalabrutinib plus Rituximab for the treatment of elderly or low- to intermediate-risk younger untreated mantle cell lymphoma

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-06 MST

Cite this

APA
Anonymous. (2025). Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma: A Single-Arm, Open-Label, Multicenter, Phase II Study. <em>Sun Yat-sen University</em>. https://clinicaltrials.gov/study/NCT06846489
Vancouver
Anonymous. Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma: A Single-Arm, Open-Label, Multicenter, Phase II Study. Sun Yat-sen University. 2025.
BibTeX
@misc{anon2025Acalab, title = {Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma: A Single-Arm, Open-Label, Multicenter, Phase II Study}, author = {Anonymous}, journal = {Sun Yat-sen University}, year = {2025}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings